COMMUNIQUÉS West-GlobeNewswire

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®
27/08/2025
BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the [...]
Evaxion to present at several conferences during the second half of 2025
27/08/2025
Evaxion will provide scientific and company updates at numerous conferences in both the US, Europe and Asia during the coming months COPENHAGEN, Denmark, August 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a [...]
Emergent BioSolutions to Participate in Upcoming Investor Conferences
27/08/2025
GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: [...]
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)
27/08/2025
US Food and Drug Administration (FDA) has granted Fast Track designation for NRX-100 in the treatment of suicidal ideation in patients with depression, including bipolar depression. NRx Pharmaceuticals is making NRX-100 [...]
24/7 Market News: Kraig Labs Prepares for High-Profile International Order as Second Production Facility Reaches Full Operational Status
27/08/2025
Specialized Spider Silk to Fulfill Demand from Iconic Global Brand, Expectations Soar for Q4 Ramp-Up DENVER, Aug. 27, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift [...]
Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
27/08/2025
Presenting Data from CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma (r/r pHGG) Patients FLORHAM PARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar [...]
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
27/08/2025
Initial collaboration led to Tyvaso DPI®, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension DANBURY, Conn. and BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD [...]
Kailera Therapeutics to Participate in Upcoming Investor Conferences
27/08/2025
WALTHAM, Mass. and SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment [...]
24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy
27/08/2025
New Peer-Reviewed Publication Highlights Landmark Meeting Co-Sponsored by LIXTE DENVER, Aug. 27, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial [...]
Sarborg Limited Closes $10 Million Seed Round to Expand Proprietary Agentic Approach
27/08/2025
Funding supports next-generation AI agent development and proprietary Intellectual Property, focused initially on pharmaceutical drug-repurposing Initial clients reporting commercial success, revolutionizing indication [...]
Disc Medicine to Participate in Upcoming Investor Conferences
27/08/2025
WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
27/08/2025
HOUSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of [...]
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences
27/08/2025
THE WOODLANDS, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at Citi's Biopharma Back to School [...]
Alpha Tau to Participate in Five September Investor Conferences
27/08/2025
JERUSALEM, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced [...]
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
27/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for [...]
Commure Ambient AI Scores High Marks in KLAS First Look Report for Automating Provider Documentation & RCM
27/08/2025
KLAS research highlights Commure’s differentiated true ambient scribe technology, seamless integrations, and white-glove support model with forward-deployed engineers MOUNTAIN VIEW, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE [...]
Profusa Announces Commercial and Clinical Collaboration with Head of Angiography, Medical University of Graz, Austria
27/08/2025
Led by Prof. Dr. Marianne Brodmann, PI of clinical studies for the Lumee™ Oxygen CE Mark, collaboration includes practice adoption and platform integration in cases and clinical study programs BERKELEY, Calif, Aug. 27, [...]
Moleculin Issues New Positive AML Overall Survival Data:
27/08/2025
Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2 nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L-7L) of 9 months (n [...]
Editas Medicine to Participate in Upcoming Investor Conferences
27/08/2025
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that [...]

Pages